Merck secures Japanese approval for subcutaneous Keytruda
Merck (MRK) has secured Japanese regulatory approval for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous injection, covering all indications currently approved for Keytruda in Japan, it said on Monday.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.